Sam Brusco, Associate Editor11.20.23
Paragonix Technologies has completed the world’s first-in-human case using its BAROguard donor lung preservation system, which earned U.S. Food and Drug Administration (FDA) 510(k) clearance in August.
The case was conducted by Duke University Medical Center’s Dr. Kunal Patel. It safely protected a pair of donor lungs across 600 miles, actively preserving and monitoring them for over six hours.
BAROguard is a hypothermic preservation system that automatically controls the donor lungs’ airway pressure when outside the body in transportation. It ensures the lungs avoid the traditional risks that occur in transport by remaining in the optimal temperature range and adhering to the clinically recommended inflation pressure range.
Real-time transmission of temperature and airway pressure data gives transplant teams visibility into the lungs’ conditions during transport to the destined recipient.
“This is an exciting time in the field of transplantation to address preservation conditions that were previously not controllable. We are steadfast in our commitment to advancing patient care, and our team is at the forefront of exploring and utilizing new technologies, Dr. Patel told the press.
“This exciting milestone serves as a testament to the BAROguard System’s potential to revolutionize lung preservation and transport,” added Lisa Anderson, Paragonix’s president and CEO. “We will continue to push the boundaries of innovation to provide more advanced tools for healthcare professionals and better outcomes for patients.”
Paragonix also shared research from a clinical study on patient outcomes after heart surgery earlier this month.
The case was conducted by Duke University Medical Center’s Dr. Kunal Patel. It safely protected a pair of donor lungs across 600 miles, actively preserving and monitoring them for over six hours.
BAROguard is a hypothermic preservation system that automatically controls the donor lungs’ airway pressure when outside the body in transportation. It ensures the lungs avoid the traditional risks that occur in transport by remaining in the optimal temperature range and adhering to the clinically recommended inflation pressure range.
Real-time transmission of temperature and airway pressure data gives transplant teams visibility into the lungs’ conditions during transport to the destined recipient.
“This is an exciting time in the field of transplantation to address preservation conditions that were previously not controllable. We are steadfast in our commitment to advancing patient care, and our team is at the forefront of exploring and utilizing new technologies, Dr. Patel told the press.
“This exciting milestone serves as a testament to the BAROguard System’s potential to revolutionize lung preservation and transport,” added Lisa Anderson, Paragonix’s president and CEO. “We will continue to push the boundaries of innovation to provide more advanced tools for healthcare professionals and better outcomes for patients.”
Paragonix also shared research from a clinical study on patient outcomes after heart surgery earlier this month.